GlassScriptPhysician profile
Jaswinder Singh
NPI 1093747677
$46,069.73
in general payments reported to CMS, 2019-2025
91 companies · $7,051 in 2025
The $7,051 reported for 2025 was more than what 85% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $7,018 · 2021: $2,570 · 2022: $3,167 · 2023: $5,473 · 2024: $3,067 · 2025: $7,051.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $12K · Consulting Fee: $3,628 · Education: $225.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $11,738.25 |
| Consulting Fee | $3,628.00 |
| Education | $224.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Foundation Medicine, INC. | $10,215.81 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $6,046.25 | 2020-2025 | Calquence, Enhertu, Tagrisso |
| Celgene Corporation | $5,911.49 | 2019-2025 | Reblozyl, Pomalyst |
| Flowonix Medical Incorporated | $3,596.53 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $1,970.72 | 2019-2025 | Kisqali, Piqray |
| Mylan INC. | $1,953.00 | 2023 | |
| Merck Sharp & Dohme LLC | $1,318.61 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Abbvie INC. | $1,244.77 | 2019-2025 | Venclexta |
| Glaxosmithkline, LLC. | $1,200.20 | 2020-2025 | Jemperli, Ojjaara, Zejula |
| Pfizer INC. | $1,156.44 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $1,003.12 | 2019-2025 | Opdivo, Opdualag, Camzyos |
| Janssen Biotech, INC. | $835.69 | 2019-2025 | Erleada, Darzalex, Talvey |
| Gilead Sciences, INC. | $615.82 | 2019-2025 | Trodelvy |
| Seagen INC. | $554.38 | 2019-2024 | Tukysa, Padcev, Adcetris |
| Tersera Therapeutics LLC | $501.68 | 2019-2025 | Zoladex, Xermelo, Quzyttir |
Show all 82 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $483.62 | 2020-2025 | |
| Amgen INC. | $471.83 | 2019-2023 | Kyprolis |
| Daiichi Sankyo INC. | $407.07 | 2020-2025 | Enhertu, Datroway, Injectafer |
| Array Biopharma INC | $400.84 | 2019-2025 | Braftovi, Mektovi, Lorbrena |
| Genzyme Corporation | $382.76 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $324.93 | 2019-2025 | Iclusig, Alunbrig, Fruzaqla |
| Genentech USA, INC. | $285.09 | 2019-2025 | Polivy, Lunsumio, Columvi |
| Astellas Pharma US INC | $282.42 | 2019-2025 | Vyloy, Padcev, Xospata |
| Kite Pharma, INC. | $270.90 | 2020-2025 | Yescarta |
| Exelixis INC. | $237.95 | 2019-2025 | Cabometyx |
| Regeneron Healthcare Solutions, INC. | $236.68 | 2021-2025 | Libtayo |
| Histosonics, INC. | $222.45 | 2024 | |
| Shockwave Medical, INC | $219.18 | 2021-2023 | Shockwave Intravascular Lithotripsy (Ivl) System With The Shockwave C2+ Coronary |
| Dendreon Pharmaceuticals LLC | $180.77 | 2021-2025 | Provenge |
| Puma Biotechnology, INC. | $180.00 | 2019-2024 | |
| Incyte Corporation | $174.80 | 2019-2024 | Monjuvi |
| Janssen Scientific Affairs, LLC | $171.57 | 2022-2023 | Darzalex, Tecvayli, Balversa |
| Caris Mpi, INC. | $160.50 | 2025 | Mi Cancer Seek |
| Pharmacyclics LLC, An Abbvie Company | $151.35 | 2020-2023 | Epkinly |
| Galvanize Therapeutics, INC | $146.84 | 2023 | Aliya System |
| Clovis Oncology, INC. | $140.96 | 2019-2020 | |
| Taiho Oncology, INC. | $140.08 | 2019-2025 | |
| Aveo Pharmaceuticals, INC. | $139.21 | 2021-2024 | Fotivda |
| Boston Scientific Corporation | $124.87 | 2020 | |
| Ipsen Biopharmaceuticals, INC | $118.06 | 2019-2024 | Onivyde |
| Pharmaessentia USA Corporation | $111.96 | 2023 | Besremi |
| Genentech, INC. | $111.86 | 2025 | Tecentriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $103.80 | 2019-2023 | Gilotrif |
| Sobi, INC | $96.75 | 2022-2025 | |
| Epizyme, INC. | $90.80 | 2020-2022 | |
| Stemline Therapeutics INC. | $83.01 | 2023-2025 | Orserdu |
| Tesaro, INC. | $75.26 | 2019 | |
| Jazz Pharmaceuticals INC. | $74.82 | 2019-2025 | |
| Kyowa Kirin, INC. | $70.57 | 2021-2025 | Poteligeo |
| Acrotech Biopharma INC. | $65.73 | 2021-2022 | |
| Lilly USA, LLC | $63.47 | 2022-2024 | Jaypirca, Verzenio |
| Sanofi-Aventis U.S. LLC | $60.45 | 2019-2021 | |
| Legend Biotech USA INC. | $59.01 | 2025 | Carvykti |
| Emd Serono, INC. | $52.79 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $51.02 | 2022-2025 | Xpovio |
| Adaptive Biotechnologies Corporation | $50.39 | 2025 | Clonoseq |
| Myovant Sciences INC. | $46.32 | 2021-2022 | |
| Sirtex Medical INC | $43.52 | 2019-2020 | |
| Springworks Therapeutics, INC. | $41.06 | 2024-2025 | Gomekli, Ogsiveo |
| Apellis Pharmaceuticals, INC. | $38.88 | 2023-2024 | Empaveli |
| Bayer Healthcare Pharmaceuticals INC. | $38.10 | 2019-2022 | |
| Myriad Genetic Laboratories, INC. | $35.68 | 2021 | |
| Blueprint Medicines Corporation | $32.42 | 2021-2023 | Ayvakit |
| Rigel Pharmaceuticals, INC. | $32.40 | 2019 | |
| Syndax Pharmaceuticals, INC. | $30.31 | 2025 | |
| Immunocore Limited | $29.76 | 2025 | Kimmtrak |
| Beigene USA, INC. | $29.00 | 2021-2022 | |
| G1 Therapeutics, INC. | $27.12 | 2022 | |
| Abbott Laboratories | $25.81 | 2023 | Absolute Pro |
| Pharmacosmos Therapeutics INC. | $24.19 | 2024 | Monoferric |
| Dova Pharmaceuticals | $19.34 | 2021 | |
| Recordati_rare_diseases_inc. | $19.29 | 2025 | Enjaymo |
| Novocure INC. | $18.47 | 2022 | |
| Janssen Pharmaceuticals, INC | $17.65 | 2019 | |
| Genmab U.S., INC. | $17.14 | 2023 | Tivdak |
| Csl Behring | $16.72 | 2025 | Privigen, Kcentra |
| Fresenius Kabi USA, LLC | $16.45 | 2025 | Stimufend |
| Geron Corporation | $15.16 | 2025 | Rytelo |
| Agios Pharmaceuticals, INC. | $14.95 | 2025 | Pyrukynd |
| Spectrum Pharmaceuticals INC. | $14.01 | 2025 | Rolvedon |
| Global Blood Therapeutics, INC. | $12.71 | 2022 | |
| Verastem, INC. | $12.34 | 2019 |
9 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jaswinder Singh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
The CSV has this whole record: totals, yearly figures, every listed company, payment types, and product associations.
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.